Patents by Inventor Christopher Ronald Sarko

Christopher Ronald Sarko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190169167
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20190169168
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Patent number: 9353090
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 31, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John David Ginn, Tamara Denise Hopkins, Michael D. Lowe, Christopher Ronald Sarko, John A. Westbrook, Maolin Yu, Zhonghua Zhang
  • Publication number: 20160024059
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 21, 2015
    Publication date: January 28, 2016
    Inventors: Jehrod Burnett BRENNEMAN, John David GINN, Tamara Denise HOPKINS, MIchael D. LOWE, Christopher Ronald SARKO, John A. WESTBROOK, Maolin YU, Zhonghua ZHANG
  • Patent number: 9150577
    Abstract: Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 6, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephen J. Boyer, Donghong Amy Gao, Xin Guo, Thomas Martin Kirrane, Jr., Christopher Ronald Sarko, Roger John Snow, Fariba Soleymanzadeh, Yunlong Zhang
  • Publication number: 20140377265
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: July 22, 2014
    Publication date: December 25, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
  • Patent number: 8906904
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: December 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John Ginn, Michael D. Lowe, Christopher Ronald Sarko, Edward S. Tasber, Zhonghua Zhang
  • Patent number: 8821871
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joanne Van Ryn, Keith Canada, Robert Copenhaver, Norbert Hauel, Tobias Litzenburger, Christopher Ronald Sarko, Sanjaya Singh, Alisa K. Waterman
  • Publication number: 20140073629
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: September 3, 2013
    Publication date: March 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Jehrod Burnett BRENNEMAN, John GINN, Michael D. LOWE, Christopher Ronald SARKO, Edward S. TASBER, Zhonghua ZHANG
  • Patent number: 8609696
    Abstract: Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: December 17, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Derek Cogan, Neil Moss, Christopher Ronald Sarko, Samantha Jayne Bamford, Pui Leng Loke, Heather Tye, Mark Whittaker
  • Patent number: 8569339
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A and B are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: October 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John D. Huber, Brian Christopher Raudenbush, Christopher Ronald Sarko
  • Publication number: 20130109679
    Abstract: Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
    Type: Application
    Filed: November 30, 2010
    Publication date: May 2, 2013
    Inventors: Stephen James Boyer, Donghong Amy Gao, Xin Guo, Thomas Martin Kirrane, JR., Christopher Ronald Sarko, Roger John Snow, Fariba Soleymanzadeh, Yunlong Zhang
  • Publication number: 20130065918
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A and B are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: March 8, 2012
    Publication date: March 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Jehrod Burnett Brenneman, John D. Huber, Brian Christopher Raudenbush, Christopher Ronald Sarko
  • Publication number: 20120276123
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: March 28, 2012
    Publication date: November 1, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
  • Patent number: 8293917
    Abstract: Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: October 23, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Christian Harcken, Thomas Wei-Ho Lee, Pingrong Liu, Jord Lord, Can Mao, Wang Mao, Brian Christopher Raudenbush, Hossein Razavi, Christopher Ronald Sarko, Alen David Swinamer
  • Publication number: 20110269742
    Abstract: Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 3, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Derek Cogan, Neil Moss, Christopher Ronald Sarko, Samantha Jayne Bamford, Pui Leng Loke, Spencer Charles R. Napier, Heather Tye, Mark Whittaker
  • Publication number: 20110230521
    Abstract: Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: May 1, 2009
    Publication date: September 22, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Brian Nicholas Cook, Christian Harcken, Thomas Wai-Ho Lee, Pingrong Liu, John Lord, CAN Mao, Wang Mao, Brain Christopher Raudenbush, Hossein Razavi, Christopher Ronald Sarko, Alan David Swinamer
  • Patent number: 8008327
    Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: August 30, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darren DiSalvo, Daniel Kuzmich, Can Mao, Hossein Razavi, Christopher Ronald Sarko, Alan David Swinamer, David Smith Thomson, Qiang Zhang
  • Patent number: 7550461
    Abstract: Disclosed are amide compounds of formula (I): wherein Ar1, Q, Y and R3-R6 of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: June 23, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Donghong Amy Gao, Daniel R. Goldberg, Abdelhakim Hammach, Ming-Hong Hao, Victor Marc Kamhi, Neil Moss, Kevin Chungeng Qian, Gregory Paul Roth, Christopher Ronald Sarko, Alan David Swinamer, Zhaoming Xiong
  • Patent number: RE46886
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 5, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John Ginn, Michael D. Lowe, Christopher Ronald Sarko, Edward S. Tasber, Zhonghua Zhang